Adherence to abiraterone or enzalutamide in elderly metastatic castration-resistant prostate cancer.

Giuseppe Luigi BannaValeria UrziaChiara BenantiAlessandra PitrèHelga LipariRosario Di QuattroUgo De GiorgiGiuseppe SchepisiUmberto BassoDavide BimbattiFrancesco RundoMassimo LibraLorenzo Malatino

Published in: Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer (2020)

Non-adherence to abiraterone or enzalutamide for mCRPC may have an impact on disease response and be related to patients' frailty, suggesting their geriatric assessment and clinical interventions to monitor and increase their adherence.

Keyphrases

prostate cancer
end stage renal disease
ejection fraction
chronic kidney disease
newly diagnosed
squamous cell carcinoma
peritoneal dialysis
glycemic control
prognostic factors
community dwelling
physical activity
type diabetes
metabolic syndrome
patient reported outcomes
patient reported
hip fracture